Global Sustained-release Medicine Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Sustained-release Medicine Market 2023 by Company, Regions, Type and Application, Forecast to 2029

According to our (Global Info Research) latest study, the global Sustained-release Medicine market size was valued at USD 35850 million in 2022 and is forecast to a readjusted size of USD 56060 million by 2029 with a CAGR of 6.6% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The main global manufacturers of sustained-release drugs are Sanofi, Novartis, Bayer, Johnson & Johnson, Takeda, AstraZeneca, AbbVie, etc. The top seven manufacturers occupy a total market share of nearly 35%, of which the largest manufacturer is Sanofi, with a market share of 10.85%. Global sustained-release drug production regions are mainly located in Europe, the United States, China, etc., of which the top two regions occupy more than 65% of the market share. In terms of their product categories, original ground medicine have a higher market share of 63.96%, while generics have a lower share.

Sustained-release Medicine refer to preparations that can be continuously released for a long time after administration to achieve long-acting effects, and the drug release is mainly a first-order rate process. Controlled release preparations (controlled release preparations) refer to the preparations that can automatically release the drug at a predetermined speed within a predetermined time, so that the blood drug concentration can be kept constant within the effective concentration range for a long time.

Since there is no difference between sustained-release preparations and controlled-release preparations in the some countries, so, in this report, Extended release (ER), Sustained release (SR), Controlled release (CR) and Delayed release (D

This report is a detailed and comprehensive analysis for global Sustained-release Medicine market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Distribution Channel. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Sustained-release Medicine market size and forecasts, in consumption value ($ Million), 2018-2029

Global Sustained-release Medicine market size and forecasts by region and country, in consumption value ($ Million), 2018-2029

Global Sustained-release Medicine market size and forecasts, by Type and by Distribution Channel, in consumption value ($ Million), 2018-2029

Global Sustained-release Medicine market shares of main players, in revenue ($ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Sustained-release Medicine

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Sustained-release Medicine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Novartis, Bayer, Johnson & Johnson and Takeda, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation

Sustained-release Medicine market is split by Type and by Distribution Channel. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Distribution Channel. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Original Ground Medicine
Generic Medicine

Market segment by Distribution Channel
Hospital
Drugstore
Other

Market segment by players, this report covers
Sanofi
Novartis
Bayer
Johnson & Johnson
Takeda
AstraZeneca
AbbVie
Pfizer
Collegium Pharmaceutical, Inc
Endo Pharmaceuticals
Shanghai Shyndec Pharmaceutical
Zhuhai Rundu Pharmaceutical
China Res Double-Crane

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Sustained-release Medicine product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Sustained-release Medicine, with revenue, gross margin and global market share of Sustained-release Medicine from 2018 to 2023.

Chapter 3, the Sustained-release Medicine competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Sustained-release Medicine market forecast, by regions, type and distribution channel, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War

Chapter 12, the key raw materials and key suppliers, and industry chain of Sustained-release Medicine.

Chapter 13, to describe Sustained-release Medicine research findings and conclusion.